Sandbox: Difference between revisions

No edit summary
No edit summary
Line 24: Line 24:
*If patient responds orally load with 25-50mg
*If patient responds orally load with 25-50mg
||
||
*Particularly useful when A-fib a/w exercise, after acute MI, or w/ thyrotoxicosis
*Particularly useful when A-fib a/w exercise, after acute [[MI]], or w/ [[thyrotoxicosis]]
*Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for acute conversion if they do not have any relative contraindications.<ref>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85</ref>
*Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for rate control if they do not have any relative contraindications.<ref>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85</ref>
||
||
*COPD
*[[COPD]]
*Asthma   
*[[Asthma]]  
*Decompensated heart failure   
*[[Decompensated heart failure]]  
*Hypotension
*[[Hypotension]]
|-
|-
| [[Esmolol]]||
| [[Esmolol]]||
Line 52: Line 52:
*Consider as initial therapy for pts with LV dysfunction who:   
*Consider as initial therapy for pts with LV dysfunction who:   
**Do not achieve rate control targets on beta blockers alone   
**Do not achieve rate control targets on beta blockers alone   
**Cannot tolerate addition of or increased doses of beta blocker due to decompensated CHF   
**Cannot tolerate addition of or increased doses of beta blocker due to decompensated [[CHF]]  
**Would have digoxin added anyway to improve CHF symptoms independent of A-fib   
**Would have [[digoxin]] added anyway to improve [[CH]]F symptoms independent of A-fib   
*Consider as initial therapy in pts with severe hypotension   
*Consider as initial therapy in pts with severe hypotension   
*Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate   
*Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate   
Line 63: Line 63:
||
||
*Consider for patients with decompensated heart failure or those with accessory pathways   
*Consider for patients with decompensated heart failure or those with accessory pathways   
*2nd-line agent for chronic rate control when BBs and CCBs, alone, combined, or when used with digoxin, are ineffective
*2nd-line agent for chronic rate control when [[BBs]] and [[CCBs]], alone, combined, or when used with [[digoxin]], are ineffective
||
||
|}
|}

Revision as of 16:48, 27 February 2015

Medication Dose Comments Contraindications
Calcium-Channel Blockers
Diltiazem
  • Bolus 0.25 mg/kg (average adult dose 20mg) over 2 min
  • If, after 15min 1st dose is tolerated but inadequate re-bolus 0.35 mg/kg
  • If patient responds start infusion at 5-15mg/hr or give PO dilt 30mg QID
  • Preferred in patients with chronic lung such as Asthma and COPD[1]
  • Decompensated heart failure
  • Preexcitation (especially in pediatrics)
  • Significant hypotension
Beta-Blockers
Metoprolol
  • Bolus 2.5-5mg IVP over 2min q5min up to 3 doses
  • If patient responds orally load with 25-50mg
  • Particularly useful when A-fib a/w exercise, after acute MI, or w/ thyrotoxicosis
  • Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for rate control if they do not have any relative contraindications.[2]
Esmolol
  • Bolus 0.5 mg/kg over one minute, followed by 50 µg/kg/min
  • If, after 4min response is inadequate, re-bolus followed by infusion of 100 µg/kg/min
  • If, after 4min response is still inadequate, try final bolus followed by infusion of 150 µg/kg/min
  • If necessary, infusion can be increased to maximum of 200 µg/kg/min after another four minutes
  • Use if unsure whether patient will tolerate a beta blocker since the duration of action is only 10 minutes
Other
Digoxin
  • 0.25 mg IV q2hr up to 1.5 mg, then 0.125-0.25 mg PO or IV QD
  • Adjust dose in presence of renal failure, amiodarone, etc
  • Consider as initial therapy for pts with LV dysfunction who:
    • Do not achieve rate control targets on beta blockers alone
    • Cannot tolerate addition of or increased doses of beta blocker due to decompensated CHF
    • Would have digoxin added anyway to improve CHF symptoms independent of A-fib
  • Consider as initial therapy in pts with severe hypotension
  • Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate
  • May take up to 6-8 hours to work
Amiodarone
  • Load 3-7 mg/kg IV over 30 min; then 1200 mg over 24hr via continuous infusion or in divided oral doses[3]
  • Consider for patients with decompensated heart failure or those with accessory pathways
  • 2nd-line agent for chronic rate control when BBs and CCBs, alone, combined, or when used with digoxin, are ineffective
  1. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011 May 10;342:d2549
  2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85
  3. Khan IA et al. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003 Jun;89(2-3):239-48.